

Full Name (Art. 1.01)	HCPs: City of Principal Practice HCOs: city where registered (Art. 3)	Country of Principal Practice	Principal Practice Address (Art. 3)	Donations and Grants to HCOs (Art. 3.01.1.a)	Contribution to Costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for Service and Consultancy (Art. 3.01.1.c & 3.01.2.c)		TOTAL
					Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract	
INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)										
				N/A	N/A					
OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons										
Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02				N/A	N/A					
Number of Recipients in aggregate disclosure - Art. 3.02				N/A	N/A	0	0	0	0	0
% of number of Recipients in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02				N/A	N/A					
INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)										
DRUŠTVA ZA NEURONAUKE SRBIJE	BEOGRAD	RS	BULEVAR DESPOTA STEFANA 142		29.875,06					29.875,06
OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons										
Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02										
Number of Recipients in aggregate disclosure - Art. 3.02				0	0	0	0	0	0	0
% of number of Recipients in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02					0%					0%
AGGREGATE DISCLOSURE										
Transfers of Value re Research & Development as defined - Article 3.04										14.876.343,33